CSL Behring's Andembry can be used to prevent recurrent attacks of hereditary angioedema (HAE) by the NHS, according to finalised guidance from reimbursement authority NICE. The just-published ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be self-administered by patients every four or eight weeks. The first-in-class drug targets ...

Shares of blood products company Haemonetics (NYSE:HAE). fell 2.1% in the morning session after Citigroup downgraded the stock to "Neutral" from "Buy." The action came from analyst Joanne Wuensch.

Fintel reports that on December 11, 2025, Citigroup downgraded their outlook for Haemonetics (NYSE:HAE) from Buy to Neutral. Analyst Price Forecast Suggests 1.06% Downside As of December 5, 2025, the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...